Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease by Salenave, Sylvie et al.
Available at:
http://hdl.handle.net/2078.1/164319
[Downloaded 2019/04/19 at 03:53:47 ]
"Ovarian macrocysts and gonadotrope-ovarian axis
disruption in premenopausal women receiving mitotane
for adrenocortical carcinoma or Cushing's disease"
Salenave, Sylvie ; Bernard, Valérie ; Do Cao, Christine ; Guignat, Laurence ;
Bachelot, Anne ; Leboulleux, Sophie ; Droumaguet, Céline ; Bry-Gauillard, Hélène ;
Pierre, Peggy ; Crinière, Lise ; Santulli, Pietro ; Touraine, Philippe ; Chanson,
Philippe ; Schlumberger, Martin ; Maiter, Dominique ; Baudin, Eric ; Young, Jacques
Abstract
Context: Mitotane is an adrenolytic and anticortisolic drug used in adrenocortical
carcinoma (ACC), Cushing's disease (CD), and ectopic ACTH syndrome. Its
effects on the ovaries are unknown. Objective: To evaluate the ovarian and
gonadotrope effects of mitotane therapy in premenopausal women. Patients:
We studied 21 premenopausal women (ACC: n=13; CD: n=8; median age 33
years, range 18-45 years) receiving mitotane at a median initial dose of 3 g/day
(range 1.5-6 g/day). Methods: Gynecological history was collected and ovarian
ultrasound was performed. Four women also underwent ovarian CT or magnetic
resonance imaging. Serum gonadotropin, estradiol (E<inf>2</inf>), androgens,
sex hormone-binding globulin (SHBG), and circulating mitotane levels were
determined at diagnosis and during mitotane therapy. Results: In the women
included, ovarian macrocysts (bilateral in 51%) were detected after a median 11
months (range: 3-36) of mitotane exposure. The median number of macrocysts
per woman ...
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Abstract
Context: Mitotane is an adrenolytic and anticortisolic drug used in adrenocortical carcinoma (ACC), Cushing’s disease (CD),
and ectopic ACTH syndrome. Its effects on the ovaries are unknown.
Objective: To evaluate the ovarian and gonadotrope effects of mitotane therapy in premenopausal women.
Patients: We studied 21 premenopausal women (ACC: nZ13; CD: nZ8; median age 33 years, range 18–45 years) receiving
mitotane at a median initial dose of 3 g/day (range 1.5–6 g/day).
Methods: Gynecological history was collected and ovarian ultrasound was performed. Four women also underwent ovarian
CT or magnetic resonance imaging. Serum gonadotropin, estradiol (E2), androgens, sex hormone-binding globulin (SHBG),
and circulating mitotane levels were determined at diagnosis and during mitotane therapy.
Results: In the women included, ovarian macrocysts (bilateral in 51%) were detected after a median 11 months
(range: 3–36) of mitotane exposure. The median number of macrocysts per woman was two (range: 1–4) and the median
diameter of the largest cysts was 50 mm (range: 26–90). Menstrual irregularities and/or pelvic pain were present in 15 out
of 21 women at macrocyst diagnosis. In two women, the macrocysts were revealed by complications (ovarian torsion and
hemorrhagic macrocyst rupture) that required surgery. Mitotane therapy was associated with a significant decrease
in androstenedione and testosterone levels and a significant increase in LH levels. Serum FSH and E2 levels were
also increased, and SHBG levels rose markedly.
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Conclusions: Mitotane therapy causes significant morphological and ovarian/gonadotrope hormonal abnormalities in
premenopausal women. Follicular thecal steroid synthesis appears to be specifically altered and the subsequent increase in
gonadotropins might explain the development of macrocysts. The mechanisms underlying these adverse effects, whose exact
prevalence in this population still needs to be determined, are discussed.
European Journal of
Endocrinology
(2015) 172, 141–149
Introduction
Mitotane (o,p’DDD) is an adrenolytic drug widely used to
treat adrenocortical malignancies (1, 2). It is also used as
anticortisolic agent in adrenocorticotropic hormone
(ACTH)-dependent Cushing’s syndrome associated with
pituitary corticotropic adenomas (3, 4, 5, 6) or with
ectopic ACTH secretion (5). Although this treatment has
been used for decades, the mechanisms of its action
on adrenal steroidogenic cells are only beginning to be
elucidated (7). One unresolved question is whether the
inhibitory effect of this drug on steroidogenesis is specific
to the adrenal cortex or also concerns other steroidogenic
glands such as the gonads. Some recent studies suggest
that the testicles may be affected (8), but the ovarian
effects of mitotane have not yet been studied, despite
the fact that Cushing’s disease (CD) and adrenocortical
carcinomas (ACCs) are more common in women and
can occur before the menopause. In this study, we describe
for the first time the ovarian hormonal and gonadotropic
impact of mitotane in 21 premenopausal patients. We
also report and discuss the unexpected occurrence of
ovarian macrocysts in the women studied.
Patients and methods
Patients
We retrospectively studied 21 women who received
mitotane monotherapy between 2008 and 2013. Eight of
them were treated for ACTH-dependent Cushing’s syn-
drome due to CD, while the remaining 13 women had
ACC and received mitotane post-operatively for its
antitumoral action as adjuvant therapy (Table 1). Six of
these latter 13 women had hypercortisolism (elevated
urinary free cortisol (UFC) and suppressed serum ACTH) at
diagnosis, but were in remission after ACC surgery and
before mitotane therapy. The diagnosis of CD was based
on clinical phenotype, associated with elevated UFC
excretion, a loss of the circadian plasma cortisol pattern,
a lack of cortisol suppression in the overnight 1-mg
dexamethasone suppression test, and not suppressed
ACTH levels. CD was finally confirmed by inferior
petrosal sinus sampling (IPSS) showing IPSS/peripheral
blood ACTH ratio O3 after CRH stimulation (9). The
ACC diagnosis was established by histological analysis
after surgery and Weiss scores were comprised between
5 and 9.
Menopausal women and women receiving anti-
gonadotrope treatment (oral contraceptives) that might
complicate the interpretation of hormone assays were
not eligible for the study. The baseline characteristics of
the 21 patients are summarized in Table 1.
Mitotane therapy
In patients with CD, the median dose of mitotane
(Lysodren 500 mg, HRA Pharma, Paris, France) was
2 g/day (range: 1.5–3.5) initially, and 1.5 g/day (0.5–3) at
the diagnosis of ovarian cysts. The median doses were
higher in patients with ACC: 4.5 g/day (3–6) initially and
2 g/day (1–3.5) at the diagnosis of ovarian cysts. Ovarian
cysts were diagnosed after a median 11 months (range
3–36) of mitotane exposure (see below).
Hormonal evaluation
Pre- and post-treatment endocrine evaluations consisted
of UFC and serum ACTH, DHEAS, follicle-stimulating
hormone (FSH), luteinizing hormone (LH), estradiol (E2),
total testosterone, D4-androstenedione and sex hormone-
binding globulin (SHBG) at baseline and at the moment
of ovarian cyst diagnosis.
Assays
Various RIA and immunoradiometric assays were used
in endocrine reference laboratories of referral centers to
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measure, respectively, urinary cortisol, circulating DHEAS,
E2, total testosterone, D4-androstenedione, and serum
ACTH, FSH, and LH. The characteristics of each hormone
assay (assay method, limit of detection, and normal range)
in each referral center are shown in Supplementary
Table 1, see section on supplementary data given at the
end of this article. Serum SHBG was measured with a solid-
phase chemiluminescent immunometric assay (Immulite;
Siemens Healthcare Diagnostic Products, Llanberis, UK)
with a detection limit of 0.02 nmol/l. The intra- and
interassay coefficient of variation (CV) values were 3.2
and 4.6% for a SHBG concentration of 56.4 nmol/l. Serum
inhibin B levels were measured with a commercial ELISA
(Serotec, Kidlington, Oxford, UK) with a detection limit
of 6 pg/ml and inter- and intra-assay CV values of 13 and
6% respectively. Serum anti-Mullerian hormone (AMH)
levels were assessed using the second-generation enzyme
immunoassay AMH-EIA (ref. A16507) provided by Beck-
man Coulter Immunotech (Villepinte, France) according to
the supplier’s instructions. Intra- and interassay CV values
were !8.2 and 11.2%, respectively, and the functional
sensitivity (i.e. the lowest concentration of AMH measured
with an interassay CV!20%) was 0.8 pmol/l.
Plasma mitotane concentrations were measured by
HPLC after an overnight fast, as described previously (10).
Intra-assay CV values were 20% at low values and 15%
at high values.
Morphological evaluation " Pelvic transabdominal and
transvaginal ultrasound examinations were performed
with 7.5-MHz probes by experienced gynecological
radiologists. Four women also underwent ovarian CT or
magnetic resonance imaging (MRI).
Statistical analysis
All results are reported as individual values in the figures
and as medians (range) in the tables and text. Baseline
and on-treatment hormone concentrations were com-
pared using the nonparametric Mann–Whitney U test or
the Wilcoxon’s signed-rank (paired) test, as appropriate.
GraphPad Prism software version 4 was used for all
analyses. P values !0.05 were considered to denote
significant differences.
Results
Menstrual status and pelvic symptoms
We observed a high frequency of menstrual disorders at
baseline in women with ACC and CD (14/21 patients,
Table 1 and Supplemental Fig. 1A, see section on
supplementary data given at the end of this article)
(present in 14/21 patients at baseline) (11). At the time
of diagnosis of ovarian cysts, 15 out of 21 patients had
Table 1 Clinical and hormonal characteristics of women with Cushing’s disease (CD) or
adrenocortical carcinoma (ACC) before mitotane therapy. To convert the values for testosterone
in ng/ml to nanomoles/l, multiply by 3.467 and to ng/dl multiply by 100. To convert the values for
D4-androstenedione in ng/ml to nanomoles/l, multiply by 3.492 and to ng/dl multiply by 100.
To convert the values for estradiol to picomoles per liter, multiply by 3.671.
Normal range in EFP
Number of patients 21
Age (years) 33 (18–45)a
BMI (kg/m2) 29 (17–47)a
Diagnosis CD: 8/21 (38%); hypercortisolism (8/8)
ACC: 13/21 (62%); hypercortisolism (6/13)
Menstrual cycles Regular: 6/21 (29%)
Amenorrhea: 7/21 (33%)
Oligomenorrhea: 7/21 (33%)
Uterus ablation: 1/21 (5%)
D4-androstenedione (ng/ml) 2.4 (0.6–12.4)a 0.4–2.0b
Testosterone (ng/ml) 0.8 (0.1–6.2)a 0.2–0.6b
Estradiol (pg/ml) 31.5 (2–56)a 34–100b
LH (IU/l) 3.0 (0.05–17)a 2.6–9.5b
FSH (IU/l) 4.6 (0.1–14)a 3.2–10b
EFP, early follicular phase.
aMedian (range).
bLower and upper limits of normal range indicated are the mean of values obtained with the different assays used
in the reference centers (see also Supplementary Table 1).
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menstrual disorders (Supplemental Fig. 1B). However,
symptoms at diagnosis of ovarian cysts were bleeding
(four patients) and pelvic pain (four other patients),
neither of which was reported to be present in any patient
at baseline (see below).
Discovery of ovarian cysts in women with CD and
ACC receiving mitotane
In the 21 patients studied herein, ovarian macrocysts
(O1 cm in diameter) were detected after a median
11 months of mitotane exposure (range 3–36 months).
The circumstances of cyst discovery were variable. In
14 patients (67%), the diagnosis was made during pelvic
ultrasound examination performed for either pelvic pain
(nZ4), or abnormal bleeding (nZ4), or oligo/amenorrhea
(nZ6). The sonographic aspects of six representative
patients are shown in Fig. 1. In four patients (19%), pelvic
ultrasound was performed after cyst discovery by CT or MRI
performed to monitor their adrenal malignant disease.
Figure 2 shows the typical aspect of the ovarian cysts in
these patients on CT (Fig. 2A, B, and C) and MRI (Fig. 2D).
The remaining three patients (14%) were examined
routinely by pelvic ultrasound, following the discovery of
this complication in the previous patients. Supplementary
Fig. 2, see section on supplementary data given at the end of
this article, shows the sonographic aspect before and after
mitotane exposure in a representative patient.
The median number of cysts per patient on ultrasound
was two (range 1–4). Out of 21 patients, 11 (52%) had
bilateral cysts. The median size of the largest cysts was
50 mm (range 26–90). The cysts were complicated in two
cases (women with ACC), by adnexal torsion in one case
and by hemorrhagic cyst rupture in the other case,
requiring emergency surgery. Four patients with particu-
larly large cysts underwent ovarian cystectomy for
diagnostic purposes.
In order to ascertain that ovarian macrocysts were
related not merely to hypercortisolism or ACC, but also
to mitotane therapy, we evaluated their frequency in
patients treated with mitotane when compared with
women with Cushing’s syndrome or ACC but not receiving
this drug. In 36 premenopausal women suffering from
untreated CD and having had an ovarian ultrasound, none
had ovarian macrocysts. This was also the case in seven
women with ACTH-independent Cushing’s syndrome,
whereas in 24 women with ACC not receiving mitotane,
ovarian macrocysts were detected in two. This comparison
(See also Supplementary Table 2, see section on supple-
mentary data given at the end of this article) indicated that
the frequency of ovarian macrocysts was significantly
higher in women receiving mitotane (P!0.001), strongly
suggesting the causal relationship between mitotane
A B
C D
E F
Figure 1
Sonographic appearance of ovarian macrocysts in six represen-
tative patients who received mitotane for adrenocortical cancer
or Cushing’s disease (see also Results). Each panel (A to F)
represents a different patient.
A
* *
**
*
*
*
B
C D
Figure 2
Aspect of ovarian macrocysts (asterisks) discovered by CT (A, B,
and C) or MRI (D) during monitoring of adrenocortical cancer
(see also Results).
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therapy and the appearance of macrocysts. Finally, we were
able to evaluate the fate of cysts in two patients with CD
who have stopped mitotane after their effective removal of
adrenocorticotropic pituitary adenoma. In both patients,
we observed a regression of ovarian cysts by means of
ultrasound scanning performed 3–4 months after discon-
tinuation of mitotane.
Mitotane levels and hormonal status at the time of
macrocyst discovery
Mitotane " Median mitotane concentrations at cyst
diagnosis were 11 mg/l (8.6–24) in patients with CD and
14.3 mg/l (5–20.5) in patients with ACC.
Hormonal status " Adrenal function "Median (range)
24 h UFC and serum DHEAS levels were reduced much
significantly during treatment with mitotane (12), respec-
tively, from 224 (25–2579) to 27.5 (0–136) mg/24 h
(P!0.001) and from 1758 (608–14 550) to 40 (0–65)
ng/ml (P!0.001).
Changes in ovarian and gonadotrope functions " Changes
from baseline in individual total testosterone, D4 andro-
stenedione, and LH levels are shown in Fig. 3. Circulating
levels of the two androgens (median; range) fell markedly
during mitotane therapy: testosterone from 0.77 (0.1–6.2)
to 0.15 (0–0.72) ng/ml (P!0.001, Fig. 3A) and
D4 androstenedione from 2.35 (0.57–12.38) to 0.69
(0.11–1.8) ng/ml (P!0.001, Fig. 3B). This was accom-
panied by a very significant increase in circulating LH:
from 3.0 (0.2–17) to 16 (3.6–30.6) IU/l (P!0.001, Fig. 3C).
Figure 4 shows changes in individual total E2, FSH, and
SHBG levels. The median (range) total E2 level increased
significantly during mitotane treatment, from 31.5 (2–56)
to 96.5 (45–385) pg/ml (P!0.001, Fig. 4A), as did the FSH
level, from 4.6 (0.2–14) to 5.35 (2.7–15) IU/l (P!0.05,
Fig. 4B). A significant increase in SHBG levels (12) was
noted during mitotane therapy (from 36.5 (15–65) to
256.5 (151–506) nmol/l, P!0.001, Fig. 4C).
In three patients (33–45 years) with CD, we measured
circulating AMH and inhibin B before and during
treatment with mitotane. Basal serum AMH levels,
measured in three patients (33–45 years) with CD, were
12, 3, and 6 pmol/l and were, respectively, at 14, 8, and 12
pmol/l during mitotane therapy (normal range in women
aged 32–42 years: 7.7–36.2). In these three patients, basal
serum inhibin B levels were 21, 11, and 20 pg/ml and,
respectively, 39, 18, and 4 pg/ml during mitotane therapy
(normal range in women aged 32–42 years: 38–96 pg/ml).
Discussion
Mitotane is widely used to treat malignant ACC and
ACTH-dependent Cushing’s syndrome (1, 2, 3, 4, 5, 6, 8, 9,
10, 12, 13). This drug, derived from DDT, acts through a
dual mechanism involving both apoptosis of adrenal
cortex cells and inhibition of adrenal steroid synthesis
(4, 7). Some ancient studies performed in canine and
bovine adrenals demonstrated that these effects could be
related to a deleterious action on mitochondrial functions
(14, 15, 16). More recently, Hescot et al. (7) showed that
mitotane significantly reduced the activity of respiratory
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Figure 3
Total (A) testosterone, (B) D4-androstenedione, and (C) LH
levels in premenopausal women with either adrenocortical
cancer or Cushing’s disease, at diagnosis and during mitotane
therapy. ***P!0.001. To convert testosterone values in ng/ml to
nmol/l, multiply by 3.467 and to convert to ng/dl multiply by
100. To convert D4-androstenedione values in ng/ml to nmol/l,
multiply by 3.492 and to convert to ng/dl multiply by 100.
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chain complex 4, leading to mitochondrial fragmentation
and cell death. Some crucial enzymes involved in steroid
synthesis are located in mitochondria; this is notably the
case of CYP11A (also called cholesterol side-chain cleavage
(scc) or P450scc), the enzyme responsible for biosynthesis
of pregnenolone, the common precursor of all adrenal,
ovarian, and testicular steroids (17). However, biosyn-
thesis of this steroid precursor requires prior translocation
of cholesterol into the mitochondria by STAR protein
(17). Mitotane might therefore, through its deleterious
effect on mitochondria, inhibit gonadal steroidogenesis,
in addition to its established effect on the adrenal cortex
(4, 7). Evidence of an effect on testicular steroidogenesis
has indeed been reported, thereby strengthening this
hypothesis (8, 12). These authors showed a decrease in
testosterone levels in men, associated with an increase in
circulating LH levels, suggesting impaired Leydig cell
steroidogenesis.
The aim of this study was to examine the ovarian
effects of chronic mitotane administration in premeno-
pausal women treated for ACC and CD. We found that
mitotane frequently led to a drastic decline in testosterone
and its immediate precursor D4-androstenedione. Before
menopause, circulating testosterone is derived from
androgenic precursors produced both by the reticulate
region of the adrenal cortex and by the theca interna cells
of large antral ovarian follicles (18). The decline in
testosterone and D4-androstenedione observed and
confirmed in this study during mitotane therapy could
partly be explained by the decline in adrenal DHEAS
described previously (12). However, the massive decline in
D4-androstenedione and testosterone suggests that ovar-
ian androgen biosynthesis ensured by cells of the theca
interna may also be affected by mitotane. This hypothesis
is supported by the very significant concomitant increase
in circulating LH levels, which could be secondary to
abolition of the negative feedback exerted by the ovaries.
Similar rises in gonadotropin levels, and particularly
LH levels, have indeed been described in situations in
which ovarian androgen biosynthesis is affected by
genetic disorders such as mutations in the LH receptor
(19, 20, 21, 22, 23), STAR (24, 25, 26), or 17-hydroxylase
(27, 28, 29). In addition, given the expected rise in serum
SHBG induced by mitotane (12, 30), the androgen
deficiency in our patients might even have been under-
estimated. However, we recognize that the intimate
mechanism underlying the very significant increase in
circulating LH levels was not demonstrated by our work
and that further studies are needed to establish precisely as
to why mitotane induces both a dramatic decrease in
androgen levels and an increase in LH levels. We must
stress that irrespective of the mechanisms possibly
involved in the decline in circulating androgen levels we
observed, this decrease could be useful, as it could prevent
the onset of clinical signs of hyperandrogenism in women
receiving this drug for hypercortisolism or ACC.
Mitotane also caused an increase in total E2, which,
although statistically significant, was inconsistent. This
might be explained, at least in part, by the rise in SHBG
levels, which itself might be related to the hepatic
estrogenic effect of mitotane (30). Indeed, SHBG carrier
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Total (A) estradiol, (B) FSH, and (C) sex hormone-binding
globulin (SHBG) levels in premenopausal women with either
adrenocortical cancer or Cushing’s disease, at diagnosis and
during mitotane therapy. *P!0.05 and *** P!0.001. To convert
estradiol values to picomoles per liter, multiply by 3.671.
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protein binds with high affinity to E2 and could thereby
reduce the metabolic clearance of E2 and lead to its
accumulation (31). This hypothesis is consistent with
what was described in women with hyperthyroidism,
which exhibits concomitant increases in SHBG, E2, and
total FSH levels (32). It is also conceivable that the very
large increase in SHBG levels could lead to a decrease in
the bioactivity of circulating E2 (33) and to an increase
in FSH levels by lifting the negative feedback effect of E2
on FSH production. The increase in E2 observed in this
study is somewhat surprising, given the decline in
androgen precursors. However, we cannot rule out the
persistence, despite mitotane therapy, of sufficient
residual ovarian androgen production by theca interna
cells, followed by local metabolization to E2 by granulosa
cells under the influence of aromatase induced by elevated
FSH levels (34). Besides the possibilities suggested above,
we cannot exclude a lack of specificity of E2 immunoassays
used in the different participating centers that could also
recognize other circulating steroids or their metabolites.
To decide between these different hypotheses, we believe
that it would be useful to assess E2 levels in premenopausal
women taking mitotane using more specific techniques
such as GCMS or LCMS.
A drawback of our study is that we could only obtain
measurements of circulating AMH and inhibin B in three
women. However, the preliminary results reported in this
study do not show a dramatic decline in AMH, and
therefore do not suggest a decline in ovarian reserve,
which is rather reassuring. However, prospective future
research, including a significant number of patients, will
be needed to actually assess the levels of these ovarian
peptides in premenopausal women treated with mitotane.
The development of ovarian macrocysts, in our
patients during mitotane therapy, was surprising as
never reported before. This is all the more curious since
this drug has been used for decades in ACC (1, 2, 12) and
CD (3, 4, 5, 6), both of which are predominantly female
diseases that can occur before menopause. How did this
adverse effect go unnoticed until now? One possible
explanation is that pelvic imaging is underused in these
women, despite their frequent gynecological symptoms.
Two-thirds of patients included in our study had pelvic
symptoms during treatment with mitotane. Menstrual
disorders such as oligomenorrhea and amenorrhea are
difficult to assign to mitotane because of their frequency
in women with hypercortisolism (11). Nevertheless, we
believe that an interview focusing on bleeding and/or
pelvic pain, which are frequent in this setting, could help
to detect this adverse effect earlier. However, we recognize
that systematic studies examining the prevalence of these
latter gynecological signs both in women with Cushing’s
syndrome and ACC, receiving mitotane or not, are still
necessary to specify their predictive value for the presence
of macrocysts.
Another drawback of our study is our inability to
establish the exact prevalence of ovarian cysts in pre-
menopausal women treated with mitotane. To define the
prevalence of ovarian complication, prospective studies,
in either women taking oral contraceptives or not, will
be needed.
In two patients with CD, we observed regression of
ovarian cysts by means of ultrasound scanning performed
3–4 months after discontinuation of mitotane. This
favorable evolution seems to reinforce the imputability
of mitotane in the development of cysts. But interestingly,
it especially suggests that this side effect could be
reversible, which is rather reassuring.
The mechanism of formation of these cysts is unclear.
We can speculate that the increase in pituitary gonado-
tropins may play a role, as in the above-mentioned genetic
diseases affecting ovarian steroidogenesis. Indeed, ovarian
macrocysts are also observed in women (XX karyotype)
with mutations of the LH receptor, STAR protein, or
17a-hydroxylase, which are associated with both a
decrease in circulating androgen levels and an increase
in gonadotropins (19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29).
Mitotane might induce the formation of these macrocysts
through a similar mechanism. If the gonadotropin
elevation indeed plays a pivotal role in the development
of these cysts, it might be possible to prevent them by
inhibiting pituitary gonadotropin secretion in women
treated with mitotane. The use of hormonal contraception
recommended for patients treated with mitotane, by
lowering circulating gonadotropins, could help prevent
the occurrence of these cysts. Pending trials of such a
preventive strategy, we believe, are unable to dictate
specific recommendations that women treated with
mitotane should receive regular ultrasound monitoring
to detect ovarian cysts before the onset of complications
such as bleeding and torsion, especially in those with
gynecological symptoms such as pelvic pain or abnormal
bleeding. In women with ACC undergoing routine
imaging usually performed for evaluation of ACC, MRI
or CT could be enough to detect macrocysts, provided that
radiologists are aware of this complication and that the
imagery properly explores the pelvic region.
Finally, in our study, we excluded postmenopausal
women and therefore we cannot exclude the possibility
that ovarian macrocysts may appear in this population.
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A specific study will be necessary to assess the frequency
of such an ovarian complication in these women.
In conclusion, we show in this study for the first time
that ovarian and gonadotropic functions are markedly
affected by mitotane in premenopausal women. This
effect is accompanied by a dramatic decrease in androgen
levels and an increase in gonadotropin levels, suggesting
impairment of the theca interna, adding to the inhibition
of adrenal androgen secretion. Ovarian macrocysts are
a frequent adverse effect of mitotane and therefore
warrant routine ovarian ultrasound screening to avoid
complications.
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